Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

An absolute, supraphysiologic elevation in GFR is observed early in the natural history in
10%–67% and 6%–73% of patients with type 1 and type 2 diabetes, respectively. Moreover …

Background: We assessed the effect of once-weekly semaglutide and once-daily liraglutide
on kidney outcomes in type 2 diabetes. Methods: Pooled (n= 12 637) and by-trial data from …

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …

The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …

Introduction: Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in
diabetes and is the most common cause of proteinuric and non-proteinuric forms of end …

Recent clinical trials in people with type 2 diabetes have demonstrated beneficial actions on
heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are …

Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of
public health. Currently, many of these patients experience progression of cardiovascular …

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease
(CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major …